Literature DB >> 12188105

A molecular basis of the therapeutic and psychoactive properties of cannabis (delta9-tetrahydrocannabinol).

Gabriel Nahas1, David J Harvey, Kenneth Sutin, Herman Turndorf, Robert Cancro.   

Abstract

All of the therapeutic properties of marihuana (analgesic, antiemetic, appetite stimulant, antiglaucoma) have been duplicated by the tetrahydrocannabinol (THC) molecule or its synthetic derivatives. Today, the molecular mechanisms of action of these compounds have led to a general understanding of the pharmacological effects of marihuana and of its therapeutic properties. These mechanisms involve the specific binding of THC to the 7-transmembrane (7TM) domain G protein-linked receptor, a molecular switch which regulates signal transduction in the cell membrane. The natural ligand of the 7TM receptor is an eicosanoid, arachidonylethanolamide (AEA), generated in the membrane and derived from arachidonic acid. THC acts as a substitute ligand to the 7TM receptor site of AEA. THC would deregulate the physiological function of the 7TM receptor and of its ligand AEA. As a result, the therapeutic effects of the drug may not be separated from its adverse psychoactive and cardiovascular effects. The binding of THC to the 7TM receptor site of AEA induces allosteric changes in the receptor sites of neurotransmitter and opiates resulting in variable interactions and pharmacological responses. The pharmacokinetics of THC with its prolonged storage in fat and its slow release result in variable and delayed pharmacological response, which precludes precise dosing to achieve timely therapeutic effects. The experimental use of THC and of its synthetic analogues, agonists, and antagonists has provided novel information in the nature of molecular signaling in the cell membrane. As a result, the relationships between allosteric receptor responsiveness, molecular configuration of proteins, and physiological regulation of cellular and organ function may be further investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12188105     DOI: 10.1016/s0278-5846(01)00245-7

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

Review 1.  The emerging role of cannabinoid neuromodulators in symptom management.

Authors:  Mellar Davis; Vincent Maida; Paul Daeninck; Joseph Pergolizzi
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.359

2.  Acute and short-term administrations of delta-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6 mice.

Authors:  Megha Oza; William Becker; Phani M Gummadidala; Travis Dias; Mayomi H Omebeyinje; Li Chen; Chandrani Mitra; Rubaiya Jesmin; Paramita Chakraborty; Mathew Sajish; Lorne J Hofseth; Koyeli Banerjee; Qian Wang; Peter D R Moeller; Mitzi Nagarkatti; Prakash Nagarkatti; Anindya Chanda
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

3.  Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.

Authors:  Prasan R Bhandari
Journal:  J Adv Pharm Technol Res       Date:  2012-10

4.  A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors:  Mark A Ware; Paul Daeninck; Vincent Maida
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

Review 5.  Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from Cannabis sativa L. Promising Compounds?

Authors:  Ersilia Nigro; Marialuisa Formato; Giuseppina Crescente; Aurora Daniele
Journal:  Molecules       Date:  2021-05-02       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.